About US
Contact us
-
Feds descend on Perrigo offices with search warrantsA number of generics makers have said that they have been asked by federal authorities to turn over info about drug pricing in a probe that has already led to charges against the execs of one company.2017/5/18
-
Eli Lilly's insulin pricing scrutiny intensifies with newly disclosed state AG probesAlready under fire for its insulin pricing, Eli Lilly faces a pair of new investigations by state attorneys general. In a securities filing, Lillydisclosedthat the Washington state attorney general i2017/5/18
-
Novo Nordisk reaches whistleblower settlement in 'white-coat' sales scheme lawsuitNovo Nordisk has moved to settle a whistleblower lawsuit alleging the company ran a “white-coat marketing scheme” to pump up sales of NovoLog, Victoza and Levemir. According to thesuit(PDF)—recentl2017/5/17
-
As Supreme Court steps into tangled biosimilars law, IP experts weigh inU.S. Supreme Court justices took their shot at picking apart the knotty Biologics Price Competition and Innovation Act on Wednesday, questioningAmgen and Sandoz attorneys about the “patent dance” lead2017/5/17
-
Novartis to pay $50M, lose some drug coverage in Korean bribery probeFor more than a year, Novartis has been under investigation in Korea for allegedly bribing doctors to pump up sales. Now, the Swiss drug giant is learning about its punishment in the country as author2017/5/16
-
J&J, Bayer face first jury trial over blockbuster Xarelto's bleeding risksThe first federal trial over the bleeding risks of Xarelto, Johnson & Johnson and Bayer’s blockbuster anticoagulant, kicks off next week, with 18,000 more cases stacked up behind it. It will be th2017/5/16
-
What if EpiPen price hikes were designed to crush rivals? Sanofi suit claims that, and much moreMylan landed in hot water with its EpiPen pricing and marketing on Capitol Hill, at the U.S. Justice Department, with New York’s attorney general and in investor class-action lawsuits. It’s beentarget2017/5/15
-
Big Pharma faces $26.5B in losses this year as next big patent cliff looms, analyst saysWith 18 branded drugs on the line, patent losses this year could jeopardize$26.5 billion in annual sales from Big Pharma,projected to be the biggest fall-off until at least 2025, according to Bernstei2017/5/15
-
Pfizer subpoenaed to testify in DOJ's antitrust probe of saline shortagesPfizer and ICU Medical, which recently bought the Hospira Infusion Systems business from Pfizer, both acknowledged on Wednesday that they have been caught up in the Justice Department’sinvestigation i2017/5/12
-
Amgen, already on PCSK9 offense, slaps Sanofi, Regeneron with Dupixent patent suitLast month, Sanofi and Regeneron sued Amgen in a move tofend offa nasty patent court battle over their new atopic dermatitis drug Dupixent. After all, the two companies were already fighting Amgen to2017/5/12